Profile data is unavailable for this security.
About the company
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.
- Revenue in USD (TTM)9.99m
- Net income in USD-119.76m
- Incorporated2016
- Employees25.00
- LocationApplied Therapeutics Inc545 FIFTH AVENUE, SUITE 1400NEW YORK 10017United StatesUSA
- Phone+1 (212) 220-9226
- Fax+1 (302) 636-5454
- Websitehttps://www.appliedtherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avid Bioservices Inc | 140.94m | -11.45m | 462.91m | 365.00 | -- | 2.52 | -- | 3.28 | -0.1816 | -0.1816 | 2.23 | 2.90 | 0.3144 | 3.18 | 5.49 | 386,131.50 | -2.55 | 10.73 | -3.11 | 14.01 | 12.52 | 22.72 | -8.12 | 25.92 | 0.8529 | -3.32 | 0.4502 | 0.00 | 24.81 | 22.72 | -99.56 | -- | 82.90 | -- |
| Shattuck Labs Inc | 1.66m | -87.30m | 464.30m | 75.00 | -- | 3.19 | -- | 280.21 | -2.05 | -2.05 | 0.0389 | 3.06 | 0.0091 | -- | -- | 22,093.33 | -47.85 | -29.14 | -53.15 | -32.42 | -- | -- | -5,268.44 | -565.33 | -- | -- | 0.00 | -- | 154.14 | -40.62 | 14.37 | -- | -19.15 | -- |
| Humacyte Inc | 0.00 | -110.78m | 464.43m | 183.00 | -- | 29.85 | -- | -- | -1.07 | -1.07 | 0.00 | 0.1307 | 0.00 | -- | -- | 0.00 | -66.63 | -- | -75.23 | -- | -- | -- | -- | -- | -- | -88.38 | 0.5819 | -- | -100.00 | -- | -825.83 | -- | -- | -- |
| Nkarta Inc | 0.00 | -117.50m | 478.70m | 150.00 | -- | 1.23 | -- | -- | -2.40 | -2.40 | 0.00 | 5.56 | 0.00 | -- | -- | 0.00 | -27.59 | -32.39 | -29.14 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
| Celcuity Inc | 0.00 | -63.78m | 480.25m | 55.00 | -- | 2.88 | -- | -- | -2.70 | -2.70 | 0.00 | 5.48 | 0.00 | -- | -- | 0.00 | -34.76 | -37.32 | -36.88 | -39.16 | -- | -- | -- | -- | -- | -- | 0.2095 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
| Applied Therapeutics Inc | 9.99m | -119.76m | 483.24m | 25.00 | -- | -- | -- | 48.36 | -1.42 | -1.42 | 0.1288 | -0.202 | 0.2145 | -- | -- | 399,720.00 | -257.01 | -140.37 | -- | -240.93 | -- | -- | -1,198.47 | -4,476.42 | -- | -- | -- | -- | -- | -- | -45.15 | -- | -- | -- |
| PetIQ Inc | 1.10bn | 2.13m | 484.95m | 1.93k | 265.93 | 2.17 | 9.88 | 0.4401 | 0.0614 | 0.0614 | 35.69 | 7.52 | 1.31 | 5.63 | 8.46 | 570,079.10 | 0.301 | -4.32 | 0.3777 | -5.23 | 22.94 | 20.05 | 0.2304 | -3.66 | 1.43 | 1.74 | 0.6671 | -- | 19.58 | 15.83 | 104.42 | -- | 4.96 | -- |
| Allogene Therapeutics Inc | 95.00k | -327.27m | 487.41m | 232.00 | -- | 0.94 | -- | 5,130.68 | -2.09 | -2.09 | 0.0006 | 3.04 | 0.0001 | -- | -- | 409.48 | -44.70 | -28.46 | -47.65 | -30.21 | -- | -- | -344,489.50 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
| Arbutus Biopharma Corp | 18.14m | -72.85m | 490.08m | 73.00 | -- | 4.36 | -- | 27.01 | -0.4386 | -0.4386 | 0.1093 | 0.6241 | 0.1068 | -- | 11.60 | 248,506.80 | -42.88 | -52.62 | -51.22 | -58.11 | -- | -- | -401.57 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
| Adlai Nortye Ltd (ADR) | 0.00 | -62.74m | 496.68m | 129.00 | -- | -- | -- | -- | -1.68 | -1.68 | 0.00 | -6.83 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -100.00 | -- | -3.73 | -- | -- | -- |
| Absci Corp | 5.72m | -110.57m | 502.46m | 155.00 | -- | 2.35 | -- | 87.87 | -1.20 | -1.20 | 0.0621 | 1.89 | 0.0212 | -- | 3.06 | 36,890.32 | -41.08 | -- | -46.22 | -- | -- | -- | -1,933.65 | -- | -- | -93.25 | 0.0467 | -- | -0.5046 | -- | -5.40 | -- | -- | -- |
| Exscientia PLC (ADR) | 25.12m | -182.64m | 503.22m | 483.00 | -- | 1.13 | -- | 20.03 | -1.45 | -1.45 | 0.1999 | 3.54 | 0.0346 | 1,096.08 | 9.86 | 52,018.25 | -25.16 | -- | -29.09 | -- | -36.47 | -- | -726.94 | -- | 6.22 | -- | 0.0505 | -- | -26.24 | -- | -22.94 | -- | -- | -- |
| Astria Therapeutics Inc | 0.00 | -72.89m | 503.46m | 59.00 | -- | 2.55 | -- | -- | -2.34 | -2.34 | 0.00 | 5.92 | 0.00 | -- | -- | 0.00 | -30.04 | -64.48 | -31.37 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
| Phibro Animal Health Corp | 982.01m | 14.80m | 503.86m | 1.92k | 34.05 | 1.86 | 10.15 | 0.5131 | 0.3654 | 0.3654 | 24.24 | 6.69 | 1.02 | 2.37 | 6.49 | 511,465.60 | 1.53 | 5.46 | 1.87 | 6.83 | 30.43 | 31.41 | 1.51 | 5.11 | 1.60 | 2.50 | 0.6369 | 42.99 | 3.78 | 3.59 | -33.69 | -13.56 | 22.80 | 3.71 |
Data as of Apr 26 2024. Currency figures normalised to Applied Therapeutics Inc's reporting currency: US Dollar USD
40.77%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Franklin Advisers, Inc.as of 31 Dec 2023 | 7.02m | 6.63% |
| Janus Henderson Investors US LLCas of 01 Mar 2024 | 6.41m | 6.06% |
| Knoll Capital Management LPas of 31 Dec 2023 | 5.47m | 5.17% |
| Propel Bio Management LLCas of 31 Dec 2023 | 5.37m | 5.08% |
| Vestal Point Capital LPas of 31 Dec 2023 | 4.16m | 3.92% |
| Perceptive Advisors LLCas of 31 Dec 2023 | 4.08m | 3.85% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 3.21m | 3.03% |
| Alyeska Investment Group LPas of 31 Dec 2023 | 2.60m | 2.46% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 2.43m | 2.29% |
| Simplify Asset Management, Inc.as of 31 Dec 2023 | 2.42m | 2.28% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
